We show that ADORA2A can serve as a promising druggable target that drives a proline metabolic-epigenetic cascade via the ERK/MYC/PYCR axis in NEPC and SCLC, suggesting a broad therapeutic implication of ADORA2A blockade in NE malignancies. The gene discussed is ADORA2A; the disease is small cell lung carcinoma.